Table 3 Treatment persistence and medication possession ratio administered by group
Group | Brand-name | Generic | Total | p |
|---|---|---|---|---|
Number of patients (%) | 3007 (22.7%) | 10, 237 (77.3%) | 13,244 (100%) | |
Time since diagnosis (months) | 2.2 (2.4) | 2.2 (2.3) | 2.2 (2.4) | 0.892 |
Median (P25–P75) | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | 2.0 (1.0–3.0) | |
Treatment possession (months) | 22.3 (20.2) | 19.6 (21.7) | 20.2 (21.2) | < 0.001 |
Median (P25–P75) | 21.0 (12.0–44.0) | 19.0 (10.0–38.0) | 20.0 (10.0–42.0) | |
Treatment duration (months) | 34.2 (20.5) | 32.0 (20.2) | 32.5 (20.3) | < 0.001 |
Median (P25–P75) | 31.0 (15.0–60.0) | 29.0 (14.0–55.0) | 29.0 (14.0–56.0) | |
Medication Possession Ratio | ||||
Average | 65.1% | 61.5% | 62.3% | < 0.001 |
95% CI | 63.8–66.2% | 60.1–62.2% | 61.8–62.9% | |
Percentage of patients on treatment at different cut-off point | Treatment persistence (HR [95% CI])a | |||
12 months | 80.3% | 77.7% | 78.3% | 0.81 [0.74–0.89], p < 0.001 |
24 months | 60.9% | 56.9% | 57.8% | 0.93 [0.87–0.99], p = 0.021 |
60 months | 25.9% | 20.7% | 21.9% | 0.86 [0.82–0.91], p < 0.001 |